Robert L. Ferris - Concepedia

Author

Robert L. Ferris

Also Known As

Adel K. El-Naggar, Ann Marie Egloff, Ferris, Robert, Ferris, Robert L, Ferris, Robert L., Helou, Vanessa, Kiemeney, L.A., Mark Kubik, Matthew J. Ferris, Niclas Rubek

1.2K

Publications

55.4K

Citations

113

H-Index

223

Concepts

All Affiliations

UPMC Hillman Cancer Center University of Pittsburgh University of Pittsburgh Medical Center The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute

About

Robert L. Ferris is an author at UPMC Hillman Cancer Center specializing in medicine, oncology, and head and neck cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	150	13.8K
2	Health Sciences	29	45	4K
3	Engineering	9	9	861
4	Public Health	5	5	244
5	Natural Sciences	1	1	36

Robert L. Ferris

395

Publications

42.9K

Citations

100

H-Index

Page 1

	Year	Citations
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, New England Journal of Medicine	2016	4.9K
Integrated Genomic Characterization of Papillary Thyroid Carcinoma Nishant Agrawal, Rehan Akbani, Bülent Arman Aksoy, Cell	2014	3K
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Oral Oncology Neoadjuvant TherapyCheckmate 141MedicineTumor Pd-l1 ExpressionPathology	2018	776
Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples Yuri E. Nikiforov, N. Paul Ohori, Steven P. Hodak, The Journal of Clinical Endocrinology & Metabolism	2011	770
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction Nicole E. Scharping, Ashley V. Menk, Rebecca S. Moreci, Immunity Cancer ImmunosurveillanceOncologyMitochondrial BiogenesisMitochondrial FunctionMedicine	2016	744
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) Ezra E.W. Cohen, R. Bryan Bell, Carlo Bifulco, Journal for ImmunoTherapy of Cancer Neoadjuvant TherapySquamous Cell CarcinomaImmunologyPathologyRecurrent Hnscc	2019	712
Lipid accumulation and dendritic cell dysfunction in cancer Donna L. Herber, Wei Cao, Yulia Nefedova, Nature Medicine Cancer ImmunosurveillanceLipid AccumulationMedicineImmunologyCancer Biology	2010	678
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer Anthony R. Cillo, Cornelius Kürten, Tracy Tabib, Immunity ImmunologyNasopharyngeal CancerPathologyImmune LandscapeNeck Pathology	2020	655
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity Abigail E. Overacre-Delgoffe, Maria Chikina, Rebekah Dadey, Cell Cancer ImmunosurveillanceImmune RegulationImmunologyTumor ImmunityImmunologic Mechanism	2017	592
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri, The Lancet Oncology Neoadjuvant TherapySquamous Cell CarcinomaMedicineHead And Neck CancerCancer Treatment	2021	582

Page 1